339 related articles for article (PubMed ID: 20035676)
1. [Radiolabeled antibodies for cancer treatment].
Barbet J; Chatal JF; Kraeber-Bodéré F
Med Sci (Paris); 2009 Dec; 25(12):1039-45. PubMed ID: 20035676
[TBL] [Abstract][Full Text] [Related]
2. Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
Sharkey RM; Goldenberg DM
J Nucl Med; 2005 Jan; 46 Suppl 1():115S-27S. PubMed ID: 15653660
[TBL] [Abstract][Full Text] [Related]
3. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
Sharkey RM; Karacay H; Cardillo TM; Chang CH; McBride WJ; Rossi EA; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7109s-7121s. PubMed ID: 16203810
[TBL] [Abstract][Full Text] [Related]
4. Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors.
Chatal JF; Davodeau F; Cherel M; Barbet J
J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S36-40. PubMed ID: 20009292
[TBL] [Abstract][Full Text] [Related]
5. Current status and perspectives in alpha radioimmunotherapy.
Chérel M; Davodeau F; Kraeber-Bodéré F; Chatal JF
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):322-9. PubMed ID: 17043629
[TBL] [Abstract][Full Text] [Related]
6. Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells.
Li XF; Kinuya S; Yokoyama K; Koshida K; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1669-74. PubMed ID: 12458402
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy and colorectal cancer.
Koppe MJ; Bleichrodt RP; Oyen WJ; Boerman OC
Br J Surg; 2005 Mar; 92(3):264-76. PubMed ID: 15739250
[TBL] [Abstract][Full Text] [Related]
8. Antibody-guided radiation therapy of cancer.
Koppe MJ; Postema EJ; Aarts F; Oyen WJ; Bleichrodt RP; Boerman OC
Cancer Metastasis Rev; 2005 Dec; 24(4):539-67. PubMed ID: 16408161
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunoconjugates for the treatment of cancer.
Kraeber-Bodéré F; Bodet-Milin C; Rousseau C; Eugène T; Pallardy A; Frampas E; Carlier T; Ferrer L; Gaschet J; Davodeau F; Gestin JF; Faivre-Chauvet A; Barbet J; Chérel M
Semin Oncol; 2014 Oct; 41(5):613-22. PubMed ID: 25440606
[TBL] [Abstract][Full Text] [Related]
10. Comparison of different classes of radionuclides for potential use in radioimmunotherapy.
Karagiannis TC
Hell J Nucl Med; 2007; 10(2):82-8. PubMed ID: 17684582
[TBL] [Abstract][Full Text] [Related]
11. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
[TBL] [Abstract][Full Text] [Related]
12. Principles of radioimmunotherapy for hematologists and oncologists.
Press OW; Rasey J
Semin Oncol; 2000 Dec; 27(6 Suppl 12):62-73. PubMed ID: 11226002
[TBL] [Abstract][Full Text] [Related]
13. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
[TBL] [Abstract][Full Text] [Related]
15. Pretargeted radioimmunotherapy of cancer: progress step by step.
Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
[TBL] [Abstract][Full Text] [Related]
16. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
17. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development.
Karacay H; Sharkey RM; Govindan SV; McBride WJ; Goldenberg DM; Hansen HJ; Griffiths GL
Bioconjug Chem; 1997; 8(4):585-94. PubMed ID: 9258459
[TBL] [Abstract][Full Text] [Related]
18. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
Alvarez RD; Huh WK; Khazaeli MB; Meredith RF; Partridge EE; Kilgore LC; Grizzle WE; Shen S; Austin JM; Barnes MN; Carey D; Schlom J; LoBuglio AF
Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520
[TBL] [Abstract][Full Text] [Related]
19. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
20. Status of radioimmunotherapy in the new millennium.
Imam SK
Cancer Biother Radiopharm; 2001 Jun; 16(3):237-56. PubMed ID: 11471488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
